Dose intense chemotherapy in the management of poor prognosis and relapsed testicular cancer: experiences and controversies

References

• Hanna NH, Einhorn L. Testicular cancer discoveries and updates. N Engl J Med. 2014 Dec 11;371:2005–2016.
   Google Scholar
• Einhorn LH, Williams SD, Ironer M, et al. The rise of maintenance therapy in disseminated testicular cancer: a Southeastern Cancer Study Group protocol. N Engl J Med. 1981;305:717–731.
   PubMed Web of Science ®Google Scholar
• Williams SD, Birch R, Irwin L, et al. Disseminated germ cell tumors: chemotherapy with cisplatin plus bleomycin plus either vinblastine or etoposide. N Eng J Med. 1987;316(1435–1440).
   Google Scholar
• IGCCCG prognostic factor based staging system in metastatic germ cell tumours. J Clin Oncol. 1997 Feb; 15(2):594–603. DOI:10.1200/JCO.1997.15.2.594
   PubMed Web of Science ®Google Scholar
• Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer. 2003;97:1869‐1875.
   PubMed Web of Science ®Google Scholar
• Albany C, Adra N, Snavel A, et al. Einhorn LH multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumours. Ann Oncol. 2018 February 1;29(2):341–346.
   PubMed Web of Science ®Google Scholar
• Simon R, Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol. 2006 Aug;3(8):406–407. Review. PubMed PMID: 16894366.
   PubMedGoogle Scholar
• Nichols CR, Williams SD, Loehrer PJ, et al. J Clin Oncol. 1991;9:1163–1172.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007 Jan 20;25(3):247–256.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Pagliaro L, Laplanche A, et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014 Dec;15(13):1442–1450. Epub 2014 Nov 13.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Flechon A. Gwenael et al. Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumours (GCT). J Clin Oncol. 2016 May;34(15_suppl):4504.
   Google Scholar
• Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol. 1998 Feb;16(2):692–701.
   PubMed Web of Science ®Google Scholar
• Toner GC, Stockler MR, Boyer MJ, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet. 2001 Mar 10;357(9258):739–745.
   PubMed Web of Science ®Google Scholar
• Bower M, Newlands ES, Holden L, et al. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol. 1997 May;8(5):477–483.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Prow DM, Do KA, et al. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20;86(10):1555–1560.
   PubMed Web of Science ®Google Scholar
• Shamash J, Powles T, Ansell W, et al. GAMEC–a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours. Br J Cancer. 2007 Aug 6;97(3):308–314. Epub 2007 Jul 3. Erratum in: Br J Cancer. 2007 Oct 22;97(8):1188.
   PubMed Web of Science ®Google Scholar
• Mee, M., Hall P, Wilson P, et al. GAMEC chemotherapy for untreated and relapsed germ cell tumours: 15 years of experience with a dose intense regimen at St Bartholomew’s hospital. Clin Oncol. 2017;29(3):e89
   Web of Science ®Google Scholar
• Loriot Y, Pagliaro L, Fléchon A, et al. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: implications for assessment of brain metastases. In Eur J Cancer. 87;2017:140–146. ISSN 0959-8049.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Nowak P, Haupt A, et al. Treatment of brain metastases in patients with testicular cancer. JClin Oncol. 1997 Apr;15(4):1449–1454. PubMed PMID: 9193339.
   PubMed Web of Science ®Google Scholar
• Hardt A, Krell J, Wilson PD, et al. Brain metastases associated with germ cell tumors may be treated with chemotherapy alone. Cancer. 2014 Jun 1 Epub 2014 Mar 25;120(11):1639–1646. PubMed PMID: 24668504.
   PubMed Web of Science ®Google Scholar
• Alifrangis C, Wilson P, Shamash J. Comment on Loriot patterns of failure in the GETUG-13 study; Dose intensity and CNS metastases. Eur J Cancer. In press.
   Google Scholar
• Christian JA, Huddart RA, Norman A, et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol. 2003 Mar 1;21(5):871–877. Review.
   PubMed Web of Science ®Google Scholar
• Huddart RA, Gabe R, Cafferty FH, et al. Cancer Research Institute Testis Cancer Clinical Studies Group. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604). Eur Urol. 2015 Mar;67(3):534–543. Epub 2014 Jul 4. PubMed PMID: 25001888; PubMed Central PMCID: PMC4410298.
   PubMed Web of Science ®Google Scholar
• Feldman D, Hu J, Dorff TB, et al. Paclitaxel, ifosfamide and cisplatin efficacy for first-line treatment of patients with intermediate or poor risk germ cell tumours. J Clin Onc. 2016 Jul 20;34(21):2478–2483. Epub 2016 May 16.
   PubMed Web of Science ®Google Scholar
• Shahidi M, Norman AR, Dearnaley DP, et al. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer. 2002;95:520–530.
   PubMed Web of Science ®Google Scholar
• Mead GM, Cullen MH, Huddart R, et al. MRC Testicular Tumour Working Party. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer. 2005 Jul 25 93(2);178–184. PubMed PMID: 15999102; PubMed Central PMCID: PMC2361542.
   PubMed Web of Science ®Google Scholar
• Miller KD, Loehrer PJ, Gonin R, et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol. 1997;15(1427–1431).
   Google Scholar
• Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005 Sep 20;23(27):6549–6555. PubMed PMID: 16170162.
   PubMed Web of Science ®Google Scholar
• Badreldin W, Krell J, Chowdhury S, et al. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach. BJU Int. 2016 Mar;117(3):418–423. Epub 2015 Jun 13. PubMed PMID: 25430674.
   PubMed Web of Science ®Google Scholar
• Nichols CR, Tricot G, Williams SD. Dose-intensive chemotherapy in refractory germ cell cancer – a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989 Jul;7(7):932–939.
   PubMed Web of Science ®Google Scholar
• Adra N, Abonour R, Althouse SK, et al. Autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University Experience. J Clin Oncol. 2017 Apr 1;35(10):1096–1102. Epub 2016 Nov 21.
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol. 2007 Jan 1;25(1):85–90. Erratum in: J Clin Oncol. 2007 May 20;25(15):2149.
   PubMed Web of Science ®Google Scholar
• Pico JL, Rosti G, Kramar A, et al. Genito-Urinary Group of the French Federation of Cancer Centers (GETUG-FNCLCC), France; European Group for Blood and Marrow Transplantation (EBMT). A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005 Jul;16(7):1152–1159. Epub 2005 May 31. PubMed PMID: 15928070.
   PubMed Web of Science ®Google Scholar
• Lorch A, Bascoul-Mollevi C, Kramar A, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011 Jun 1;29(16):2178–2184. Epub 2011 Mar 28.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Coinu A, Rosti G, et al. Salvage treatment for testicular cancer with standard- or high-dose chemotherapy: a systematic review of 59 studies. Med Oncol. 2017 Aug;34(8):133. Epub 2017 Jun 26. Review. PubMed PMID: 28653284.
   PubMed Web of Science ®Google Scholar
• Lauritsen J, Kier MG, Mortensen MS, et al. Germ cell cancer and multiple relapses: toxicity and survival. J Clin Oncol. 2015 Oct 1;33(28):3116–3123. Epub 2015 Aug 3. PubMed PMID: 26240225.
   PubMed Web of Science ®Google Scholar